Retinoblastoma Pathway Deregulatory Mechanisms Determine Clinical Outcome in High-Grade Serous Ovarian Carcinoma

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2013.218
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

2019English

Clinical Relevance of Gain-Of-Function Mutations of P53 in High-Grade Serous Ovarian Carcinoma

PLoS ONE
Multidisciplinary
2013English

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

HMGA2: A Biomarker Significantly Overexpressed in High-Grade Ovarian Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2010English

Erratum To: Tubal Precursor Lesions in High Grade Serous Ovarian Carcinoma

Indian Journal of Gynecologic Oncology
GynecologyOncologyObstetrics
2016English

Aurora Kinase a Expression Predicts Platinum-Resistance and Adverse Outcome in High-Grade Serous Ovarian Carcinoma Patients

Journal of Ovarian Research
GynecologyOncologyObstetrics
2016English

Distinct Gene Expression Profiles Associated With Clinical Outcomes in Patients With Ovarian Clear Cell Carcinoma and High-Grade Serous Ovarian Carcinoma

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Amplification of the Ch19p13.2 NACC1 Locus in Ovarian High-Grade Serous Carcinoma

Modern Pathology
Forensic MedicinePathology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy